ISSN:
1432-198X
Keywords:
Growth hormone
;
End-stage renal disease
;
Dialysis
;
Transplant
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The minimal effective dose of growth hormone (GH) to promote growth in children on dialysis or following renal transplantation remains unsettled. In order to study the issue, “low-dose” GH was administered to children with end-stage renal disease (ESRD) receiving chronic automated peritoneal dialysis (APD,n = 6, 4 males, 2 females) or following renal transplantation (T,n = 9, 8 males, 1 female). No APD patient was GH deficient, while 1 T patient (no. 2) had data consistent with GH deficiency, although he was obese (body mass index = 34 kg/m2). The mean dose of GH after 6 and 12 months of treatment was 0.16±0.02 and 0.22±0.07 versus 0.16±0.03 and 0.27±0.21 mg/kg per week for APD and T patients, respectively. When analyzing all patients, there were no significant differences before or after 6 and 12 months of GH therapy within or between the two groups, in terms of height velocity, bone age, renal function (in the T group) and height Z-scores (Z-Ht). However, the height velocity Z-score (Z-HV) increased significantly at 6 and 12 months compared with baseline in the APD patients only (P 〈 0.05). When the 2 T patients with the most impaired renal function were excluded from the analysis, Z-HV also increased significantly in the T patients after 12 months of GH (P 〈 0.02). We conclude that following “low-dose” GH therapy, children with ESRD treated with APD or T have similar increases in HV, allowing maintenance of Z-Ht but not “catch-up” growth.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02254198
Permalink
